Year All20242023 December 13, 2024 Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million Read More November 7, 2024 Palvella Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations Read More October 17, 2024 Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer Read More October 15, 2024 Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference Read More October 3, 2024 Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations Read More July 24, 2024 Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Read More
December 13, 2024 Palvella Therapeutics Announces Closing of Merger with Pieris Pharmaceuticals and Concurrent Private Placement of $78.9 Million Read More
November 7, 2024 Palvella Therapeutics Announces First Patient Dosed in Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations Read More
October 17, 2024 Palvella Therapeutics Appoints Matthew E. Korenberg as Chief Financial Officer Read More
October 15, 2024 Palvella Therapeutics Announces Presentations at the 12th Pediatric Dermatology Research Alliance (PeDRA) Annual Conference Read More
October 3, 2024 Palvella Therapeutics Awarded Up to $2.6 million Grant from the U.S. Food and Drug Administration (FDA) Office of Orphan Products Development to Support Phase 3 Single-Arm, Baseline-Controlled Trial in Microcystic Lymphatic Malformations Read More
July 24, 2024 Palvella Therapeutics and Pieris Pharmaceuticals Announce Definitive Merger Agreement Read More
